Researchers from UC Santa Barbara have developed a method by which to deliver antibodies to the kidney to curb a specific type of cyst growth that gives rise to polycystic kidney disease, which is inherited and has no known cure.
Despite "continued progress" during a drug delivery collaboration with Johnson & Johnson spinoff Zosano, Novo Nordisk has discontinued a partnership, Zosano said Monday in a statement.
Pfizer just announced that the FDA agreed to review a daily, 11-milligram modified-release tablet of its rheumatoid arthritis drug Xeljanz for patients who don't respond adequately to methotrexate (marketed as Rheumatrex and Trexall).
China's Guangxi Wuzhou Zhongheng Group disclosed that it intends to purchase a 10% stake in Israeli pharma company Oramed for $52 million, in return for exclusive Chinese distribution rights to its oral insulin following regulatory approval, according to a briefing from Reuters.
Cynapsus kicked off patient enrollment in its Phase III clinical trial of sublingual apomorphine for Parkinson's patients who stop responding to levodopa.
Langer Lab startup SQZ Biotech raised $5 million in a Series A round led by Polaris Venture Partners to support its method to gain entry into a cell's membrane by first squeezing it through a device.
Pennsylvania-based OptiNose, the creator of a bidirectional device for nasal medications, garnered positive results in a late-stage trial for its nasal polyp treatment. The company adds the anti-inflammatory treatment to its clinical lineup of migraine and autism candidates, both of which use the same delivery tech.
Hydrogels are known to give drugs an edge when it comes to quick deliverability and simple application, but their long-term efficacy has come into question as their release rates are difficult to control. Researchers in Singapore have developed a new kind of hydrogel that prevents this premature release and allows for fewer doses in patients with chronic diseases like hepatitis C.
RNAi specialist Alnylam said that development of its early-stage subcutaneous compound for hemophilia and rare bleeding will be accelerated following ongoing Phase I trial results, which indicated that the candidate can knock down levels of the anticoagulant known as antithrombin by up to 86%. Pivotal trials for FDA approval are slated to begin in mid-2016.
The FDA warned that a transdermal patch used to treat ADHD in children and adolescents can lead to chemical leukoderma, or permanent skin discoloration, as a result of the skin's repeated exposure to specific chemical compounds.
Materials scientists are once again looking to nature to solve a drug delivery problem. This time, researchers from Harvard have investigated the way in which living tissues bring liquids where they're needed and ultimately secrete them--and they developed a synthetic system that mimics the process.
Two companies with a focus on drug delivery are making a go at an IPO, joining several biotechs that have thrown their hats in the ring in the last few days. Belgian gene therapy specialist Celyad--formerly Cardio3--has priced its offering on the Nasdaq for $100 million, and ADHD formulator Neos Therapeutics filed with the SEC to raise up to $69 million.
Bayer is collaborating with Johns Hopkins University's Wilmer Eye Institute to develop new forms of drug delivery to the back of the eye. Targeted diseases include age-related macular degeneration and diabetic macular edema, which both result in in vision loss.
A PhD candidate at Canada's McMaster University is developing a drug delivery contact lens for glaucoma patients because eye drops are incredibly inefficient and deliver only 5% of the active ingredient they carry to the cornea.
Acorda Therapeutics moved a step closer to collecting the payoff from its $525 million acquisition of Civitas, maker of an inhaled levodopa, in the scramble to deliver an improved formulation of the standard Parkinson's med. The conventional oral formulation suffers from unpredictable absorption in the bloodstream and a wearing-off effect after about 5 years.
UPDATED: Microchips Biotech partners with Teva on wireless drug delivery, announces new CEO, raises $18M in financing
On the heels of Microchips Biotech's $35 million partnership with Teva to apply the company's electronic drug delivery implant for administration over months to years toward at least one disease area, the company announced that Cheryl Blanchard, the former chief scientific officer of Zimmer, will become its new CEO.
Two new studies presented at the annual American Diabetes Association have shown the benefits of the hormone glucagon--used to control the concentration of glucose in the bloodstream--in patients with Type 1 diabetes. One is a nasal powder to treat hypoglycemia in children and the other is an advance in the development of an effective artificial pancreas, finding the addition of glucagon could reduce nighttime hypoglycemia.
A study found that tablets increase compliance among postmenopausal women suffering from vaginal atrophy when compared to cream. Almost 90% of patients who took the cream stopped using it after the first prescription, compared to 58% of patients who were on Novo Nordisk's Vagifem 10 milligram estradiol tablets.
Bolstering recent growth in the research of progesterone-loaded intravaginal rings as contraceptives, the World Health Organization has voiced its approval, adding the delivery method to its 2015 essential medicines list, particularly for postpartum women and with a focus on the developing world.
It's been a busy week on Wall Street for Parkinson's players all over the globe. Finland's Biotie Therapies saw its stock surge upon debut on the Nasdaq, Canada's Cynapsus plans to hit the exchange this week, and Israel's Intec Pharma plans to conduct an IPO shortly.